X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2083) 2083
Publication (150) 150
Book / eBook (52) 52
Book Chapter (49) 49
Book Review (37) 37
Dissertation (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1350) 1350
index medicus (1246) 1246
hematology (937) 937
hematological malignancies (816) 816
male (763) 763
female (758) 758
oncology (648) 648
cancer (562) 562
adult (561) 561
middle aged (559) 559
aged (442) 442
leukemia (394) 394
adolescent (287) 287
chemotherapy (275) 275
transplantation (272) 272
analysis (265) 265
care and treatment (254) 254
animals (249) 249
acute myeloid-leukemia (235) 235
research (234) 234
risk factors (228) 228
health aspects (216) 216
medicine & public health (216) 216
child (213) 213
treatment outcome (210) 210
stem cells (203) 203
aged, 80 and over (193) 193
young adult (193) 193
retrospective studies (188) 188
immunology (177) 177
patients (169) 169
hematological malignancy (167) 167
medicine (166) 166
lymphomas (163) 163
acute lymphoblastic-leukemia (154) 154
child, preschool (154) 154
prognosis (154) 154
haematological malignancy (152) 152
blood (150) 150
hematopoietic stem cells (148) 148
pharmacology & pharmacy (148) 148
diagnosis (144) 144
mortality (143) 143
children (139) 139
lymphoma (139) 139
therapy (137) 137
medical research (131) 131
stem-cell transplantation (128) 128
survival (128) 128
bone-marrow-transplantation (126) 126
neutropenia (120) 120
infant (115) 115
apoptosis (114) 114
disease (113) 113
mutation (113) 113
risk (113) 113
tumors (113) 113
hematological diseases (112) 112
bone marrow (111) 111
research article (111) 111
hematology, oncology and palliative medicine (107) 107
hematologic neoplasms - drug therapy (106) 106
hematologic neoplasms - therapy (106) 106
haematological malignancies (105) 105
chronic lymphocytic-leukemia (104) 104
toxicity (104) 104
prospective studies (102) 102
antineoplastic agents - therapeutic use (101) 101
cell biology (101) 101
multiple myeloma (101) 101
proteins (100) 100
infectious diseases (98) 98
epidemiology (96) 96
medicine, experimental (96) 96
hematologic neoplasms - complications (95) 95
hematological parameters (95) 95
genetic aspects (92) 92
pediatrics (92) 92
diseases (90) 90
clinical trials (87) 87
gene expression (87) 87
antineoplastic combined chemotherapy protocols - therapeutic use (86) 86
multiple-myeloma (86) 86
hematopoietic stem cell transplantation (84) 84
risk-factors (82) 82
versus-host-disease (82) 82
biology (81) 81
infection (81) 81
cancer-patients (79) 79
disease-free survival (79) 79
incidence (77) 77
internal medicine (77) 77
drug therapy (76) 76
science (76) 76
transplantation, homologous (76) 76
usage (76) 76
acute myeloid leukemia (75) 75
mice (75) 75
stem cell transplantation (75) 75
antifungal agents - therapeutic use (74) 74
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (40) 40
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Online Resources - Online (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Markham Stouffville Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2162) 2162
Spanish (10) 10
French (7) 7
Japanese (6) 6
Russian (6) 6
German (5) 5
Portuguese (2) 2
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 08/2017, Volume 178, Issue 4, pp. 571 - 582
The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and... 
toxicity | multiple myeloma | proteasome inhibitor | Hematology | dosing | ixazomib | DEXAMETHASONE | SAFETY | BORTEZOMIB | PHARMACOKINETICS | PHASE-1 | LENALIDOMIDE | PERIPHERAL NEUROPATHY | QUALITY-OF-LIFE | HEMATOLOGY | ORAL PROTEASOME INHIBITOR | AMERICAN SOCIETY | Glycine - analogs & derivatives | Peripheral Nervous System Diseases - chemically induced | Follow-Up Studies | Glycine - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Nausea - therapy | Aged, 80 and over | Adult | Leukocyte Count | Glycine - administration & dosage | Thalidomide - adverse effects | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Dexamethasone - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Peripheral Nervous System Diseases - therapy | Thalidomide - administration & dosage | Hematologic Diseases - therapy | Vomiting - chemically induced | Platelet Count | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Boron Compounds - adverse effects | Aged | Vomiting - therapy | Complications and side effects | Corticosteroids | Analysis | Multiple myeloma | Nausea | Backache | Lithium compounds | Thrombocytopenia | Edema | Back pain | Dexamethasone | Toxicity | Exanthema | Feasibility studies | Diarrhea | Peripheral neuropathy | Patients | Bleeding | Side effects | Pain | Vomiting | Constipation | Tourmaline | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
Annals of Hematology, ISSN 0939-5555, 5/2012, Volume 91, Issue 5, pp. 767 - 774
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 11/2019, Volume 9, Issue 1, pp. 1 - 9
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune... 
EFFICACY | ITP | ROMIPLOSTIM | PURPURA | MULTIDISCIPLINARY SCIENCES | DOUBLE-BLIND | ELTROMBOPAG | CANCER | REMISSION | Thrombocytopenia | Splenectomy | Agonists | Patients | Risk factors | Immunosuppressive agents | Thrombopoietin
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2008, Volume 143, Issue 2, pp. 222 - 229
Journal Article